TP53INP1 as new therapeutic target in castration-resistant prostate cancer

Prostate

Volumn 72, Issue 12, 2012, Pages 1286-1294

  Giusiano, Sophie ^a,b,c   Baylot, Virginie ^b,c   Andrieu, Claudia ^b,c   Fazli, Ladan ^d   Gleave, Martin ^d   Iovanna, Juan Lucio ^b,c   Taranger Charpin, Colette ^a,b,c   Garcia, Stéphane ^a,b,c   Rocchi, Palma ^b,c  

^a HÔPITAL NORD   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSERM   (France)

^d VANCOUVER PROSTATE CENTRE   (Canada)

Author keywords

antisense oligonucleotide; castration resistant prostate cancer; hormone therapy; tissue micro array; TP53INP1

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DOCETAXEL; MESSENGER RNA; ONCOPROTEIN; PROTEIN TP53INPI; RNA 28S; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER RELAPSE; CASTRATION RESISTANT PROSTATE CANCER; CELL STRAIN LNCAP; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; DENSITOMETRY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TISSUE MICROARRAY; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; CARRIER PROTEINS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HEAT-SHOCK PROTEINS; HUMANS; MALE; MICE; MICE, NUDE; OLIGONUCLEOTIDES, ANTISENSE; ORCHIECTOMY; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864280130     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22477     Document Type: Article

References (33)

1. Crawford ED,. Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology 2009; 73: S4-S10.
2. Dowling AJ, Tannock IF,. Systemic treatment for prostate cancer. Can Treat Rev 1998; 24: 283-301. (Pubitemid 28488282)
3. Fusi A, Procopio G, Della Torre S, Ricotta R, Bianchini G, Salvioni R, Ferrari L, Martinetti A, Savelli G, Villa S, Bajetta E,. Treatment options in hormone-refractory metastatic prostate carcinoma. Tumori 2004; 90: 535-546. (Pubitemid 40288335)
4. Denmeade SR, Isaacs JT,. Programmed cell death (apoptosis) and cancer chemotherapy. Cancer Control 1996; 3: 303-309. (Pubitemid 26302008)
5. Denmeade SR, Isaacs JT,. Activation of programmed (apoptotic) cell death for the treatment of prostate cancer. Adv Pharmacol 1996; 35: 281-306.
6. Denmeade SR, Lin XS, Isaacs JT,. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996; 28: 251-265. (Pubitemid 26119117)
7. Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE, Veltri RW, Walsh PC, Isaacs JT,. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995; 1: 473-480.
8. Pinski J, Parikh A, Bova GS, Isaacs JT,. Therapeutic implications of enhanced G(0)/G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts. Cancer Res 2001; 61: 6372-6376. (Pubitemid 32783240)
9. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED,. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520. (Pubitemid 39315318)
10. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512. (Pubitemid 39315317)
11. Gallagher E, Gapstur R,. Hormone-refractory prostate cancer: A shifting paradigm in treatment. Clin J Oncol Nurs 2006; 10: 233-240.
12. Giusiano S, Garcia S, Andrieu C, Dusetti NJ, Bastide C, Gleave M, Taranger-Charpin C, Iovanna JL, Rocchi P,. TP53INP1 overexpression in prostate cancer correlates with poor prognostic factors and is predictive of biological cancer relapse. The Prostate 2011; DOI: 10.1002/pros.21412.
13. Rocchi P, Muracciole X, Fina F, Mulholland DJ, Karsenty G, Palmari J, Ouafik L, Bladou F, Martin PM,. Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft. Oncogene 2004; 23: 9111-9119. (Pubitemid 40013078)
14. Rocchi P, Boudouresque F, Zamora AJ, Muracciole X, Lechevallier E, Martin PM, Ouafik L,. Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines. Cancer Res 2001; 61: 1196-1206. (Pubitemid 32174443)
15. Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J,. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999; 5: 2891-2898. (Pubitemid 29493968)
16. Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K, Gleave M,. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004; 64: 6595-6602. (Pubitemid 39297919)
17. Lucas A, Petrylak DP,. The case for early chemotherapy for the treatment of metastatic disease. J Urol 2006; 176: S72-S75. (Pubitemid 44649300)
18. Okamura S, Arakawa H, Tanaka T, Nakanishi H, Ng CC, Taya Y, Monden M, Nakamura Y,. p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. Mol Cell 2001; 8: 85-94. (Pubitemid 32772907)
19. Tomasini R, Samir AA, Pebusque MJ, Calvo EL, Totaro S, Dagorn JC, Dusetti NJ, Iovanna JL, Tomasini R, Samir AA, Vaccaro MI, Pebusque MJ, Dagorn JC, Iovanna JL, Dusetti NJ,. P53-dependent expression of the stress-induced protein (SIP) molecular and functional characterization of the stress-induced protein (SIP) gene and its two transcripts generated by alternative splicing. SIP induced by stress and promotes cell death. Eur J Cell Biol 2002; 81: 294-301.
20. Tomasini R, Samir AA, Vaccaro MI, Pebusque MJ, Dagorn JC, Iovanna JL, Dusetti NJ,. Molecular and functional characterization of the stress-induced protein (SIP) gene and its two transcripts generated by alternative splicing. SIP induced by stress and promotes cell death. J Biol Chem 2001; 276: 44185-44192.
21. Tomasini R, Samir AA, Carrier A, Isnardon D, Cecchinelli B, Soddu S, Malissen B, Dagorn JC, Iovanna JL, Dusetti NJ,. TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity. J Biol Chem 2003; 278: 37722-37729. (Pubitemid 37175297)
22. Cano CE, Gommeaux J, Pietri S, Culcasi M, Garcia S, Seux M, Barelier S, Vasseur S, Spoto RP, Pebusque MJ, Dusetti NJ, Iovanna JL, Carrier A,. Tumor protein 53-induced nuclear protein 1 is a major mediator of p53 antioxidant function. Cancer Res 2009; 69: 219-226.
23. Jiang PH, Motoo Y, Garcia S, Iovanna JL, Pebusque MJ, Sawabu N,. Down-expression of tumor protein p53-induced nuclear protein 1 in human gastric cancer. World J Gastroenterol 2006; 12: 691-696. (Pubitemid 43380749)
24. Gironella M, Seux M, Xie MJ, Cano C, Tomasini R, Gommeaux J, Garcia S, Nowak J, Yeung ML, Jeang KT, Chaix A, Fazli L, Motoo Y, Wang Q, Rocchi P, Russo A, Gleave M, Dagorn JC, Iovanna JL, Carrier A, Pebusque MJ, Dusetti NJ,. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA 2007; 104: 16170-16175. (Pubitemid 350099380)
25. Gommeaux J, Cano C, Garcia S, Gironella M, Pietri S, Culcasi M, Pebusque MJ, Malissen B, Dusetti N, Iovanna J, Carrier A,. Colitis and colitis-associated cancer are exacerbated in mice deficient for tumor protein 53-induced nuclear protein 1. Mol Cell Biol 2007; 27: 2215-2228. (Pubitemid 46418477)
26. Taieb D, Giusiano S, Sebag F, Marcy M, de Micco C, Palazzo FF, Dusetti NJ, Iovanna JL, Henry JF, Garcia S, Taranger-Charpin C,. Tumor protein p53-induced nuclear protein (TP53INP1) expression in medullary thyroid carcinoma: A molecular guide to the optimal extent of surgery? World J Surg 2010; 34: 830-835.
27. Neugarten J, Ding Q, Friedman A, Lei J, Silbiger S,. Sex hormones and renal nitric oxide synthases. J Am Soc Nephrol 1997; 8: 1240-1246. (Pubitemid 27493628)
28. Gleave ME, Zellweger T, Chi K, Miyake H, Kiyama S, July L, Leung S,. Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer. Invest New Drugs 2002; 20: 145-158. (Pubitemid 34632652)
29. Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D, Gleave ME,. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005; 97: 1287-1296. (Pubitemid 41535369)
30. Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, Nelson C, Gleave M,. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res 2005; 65: 11083-11093. (Pubitemid 41713379)
31. Hirte HW, Higano CS, Gleave M, Chi KN,. Phase I trial OGX-427, a 2' methoxyethyl antisense oligonucleotide (ASO), against Hsp27: Final results. J Clin Oncol 2010; 28: Abstract 3077.
32. Hotte SJ, Yu EY, Hirte HW, Higano CS, Gleave M, Chi KN,. OGX-427, a 2' methoxyethyl antisense oligonucleotide (ASO), against Hsp27: Results of a first-in-human trial. J Clin Oncol 2009; 27: Abstract 3506.
33. Monia BP, Sasmor H, Johnston JF, Freier SM, Lesnik EA, Muller M, Geiger T, Altmann KH, Moser H, Fabbro D,. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc Natl Acad Sci USA 1996; 93: 15481-15484. (Pubitemid 27009624)